ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO162

Clinical Implications of Radiopharmaceutical Uptake in the Skull as a New Marker of CKD-MBD: Findings of Bone Scintigraphy

Session Information

  • CKD-MBD: Clinical
    October 24, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

  • 502 Bone and Mineral Metabolism: Clinical

Authors

  • Kim, Keunyoung, Pusan National University School of Medicine, Busan, Korea (the Republic of)
  • Song, Sang Heon, Pusan National University School of Medicine, Busan, Korea (the Republic of)
Background

The aim of this study is to evaluate the potential role of radiopharmaceutical uptake in skull using bone scintigraphy as a new objective maker for CKD-MBD.

Methods

We retrospectively reviewed 122 CKD patients (M:F, 70:52) who were evaluated with bone scintigraphy. The control of 195 subjects (M:F, 66:129) who have no evidence of disease state of the breast cancer for female and the prostate cancer for male were also recruited. The quantitative indices were defined as the radiopharmaceutical uptake in skull and the ratio of the skull to the ilium (SIR). The bone mineral density (BMD) values and trabecular bone score (TBS) were acquired from dual energy X-ray absoroptiometry (DXA).

Results

In all enrolled CKD patients, median TBS showed deteriorated state compared with control group. The SIR had negatively correlation with DXA values; lumbar spine (r =-0.309, P<0.001); femoral neck (r=-0.262, P<0.001), total femur (r =-0.264, P<0.001) and TBS (r=-0.251, P<0.001). SIR and TBS were remained as the independent variables showed significant correlation with levels of parathyroid hormone, calcium and creatinine in CKD patients using multiple regression.

Conclusion

The SIR was significant for the assessment of metabolic status of CKD-MBD and may therefore potentially be used as an objective tool for the assessment of bone health in CKD patients.

Figure 1. Quantitative Analysis of Bone scan

Figure 2. Representative results from the analysis
A. All values from DXA were significantly lower in the CKD patients compared with the control group.
B. The radioactivity counts in the skull was significantly higher in the CKD patients.
C. The normalized value of SIR showed exaggerated the difference between CKD and control.